JNJ vs SLRX

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

SLRX (Salarius Pharmaceuticals, Inc.) was acquired by VolitionRx Limited (VNRX) on October 18, 2023, and subsequently delisted. As of today, 2026-03-29, it does not exist as an independent publicly traded entity with any growth prospects. The quoted current price of $7.62 is an anomaly for a delisted ticker and does not reflect a liquid, investable asset. There have been no material changes since ...